Novel oral poliovirus vaccine type 2 (nOPV2) is being developed to reduce the rare occurrence of disease and outbreaks associated with the genetic instability of the Sabin vaccine strains. Children aged 1 to 5 years were enrolled in two related clinical studies to assess safety, immunogenicity, shedding rates and properties of the shed virus following vaccination with nOPV2 (two candidates) versus traditional Sabin OPV type 2 (mOPV2). The anticipated pattern of reversion and increased virulence was observed for shed Sabin-2 virus, as assessed using a mouse model of poliovirus neurovirulence. In contrast, there were significantly reduced odds of mouse paralysis for shed virus for both nOPV2 candidates when compared to shed Sabin-2 virus. Next-generation sequencing of shed viral genomes was consistent with and further supportive of the observed neurovirulence associated with shed Sabin-2 virus, as well as the reduced reversion to virulence of shed candidate viruses. While shed Sabin-2 showed anticipated A481G reversion in the primary attenuation site in domain V in the 5' untranslated region to be associated with increased mouse paralysis, the stabilized domain V in the candidate viruses did not show polymorphisms consistent with reversion to neurovirulence. The available data from a key target age group for outbreak response confirm the superior genetic and phenotypic stability of shed nOPV2 strains compared to shed Sabin-2 and suggest that nOPV2 should be associated with less paralytic disease and potentially a lower risk of seeding new outbreaks.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8837630 | PMC |
| http://dx.doi.org/10.1038/s41541-022-00437-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
From vaccine to pathogen: Modeling Sabin 2 vaccine virus reversion and evolutionary epidemiology in Matlab, Bangladesh.
Virus Evol
July 2023
Institute for Disease Modeling, Bill and Melinda Gates Foundation, 500 5th Ave N, Seattle, WA 98109, USA.
The oral poliovirus vaccines (OPVs) are one of the most effective disease eradication tools in public health. However, the OPV strains are genetically unstable and can cause outbreaks of circulating, vaccine-derived Type 2 poliovirus (cVDPV2) that are clinically indistinguishable from wild poliovirus (WPV) outbreaks. Here, we developed a Sabin 2 reversion model that simulates the reversion of Sabin 2 to reacquire a WPV-like phenotype based on the clinical differences in shedding duration and infectiousness between individuals vaccinated with Sabin 2 and those infected with WPV.
View Article and Find Full Text PDFMetagenomic sequencing, molecular characterization, and Bayesian phylogenetics of imported type 2 vaccine-derived poliovirus, Spain, 2021.
Front Cell Infect Microbiol
May 2023
Enterovirus and Viral Gastroenteritis Unit/National Polio Laboratory, National Centre for Microbiology, Instituto de Salud Carlos III, Madrid, Spain.
Introduction: In 2021, a type 2 vaccine-derived poliovirus (VDPV2) was isolated from the stool of a patient with acute flaccid paralysis (AFP) admitted to Spain from Senegal. A virological investigation was conducted to characterize and trace the origin of VDPV2.
Methods: We used an unbiased metagenomic approach for the whole-genome sequencing of VDPV2 from the stool (pre-treated with chloroform) and from the poliovirus-positive supernatant.
Genetic and epidemiological description of an outbreak of circulating vaccine-derived polio-virus type 2 (cVDPV2) in Angola, 2019-2020.
Vaccine
April 2023
US Centers for Disease Control and Prevention, Angola Country Office, R. Houari Boumediene 32, Luanda, Angola.
Article Synopsis
- Angola reported its first poliomyelitis case in six years, involving circulating vaccine-derived poliovirus type 2 (cVDPV2), with a total of 141 cases across the country from 2019 to 2020, particularly in Luanda, Cuanza Sul, and Huambo.
- The spread of cVDPV2 followed five distinct genetic emergence groups linked to earlier cases in the Democratic Republic of Congo, with a peak of 15 cases occurring in October 2019.
- Despite challenges in surveillance due to the COVID-19 pandemic, by May 2021, evidence indicated that Angola had successfully interrupted cVDPV2 transmission, but improvements in surveillance and response measures were needed for any future outbreaks.
Genetic and phenotypic stability of poliovirus shed from infants who received novel type 2 or Sabin type 2 oral poliovirus vaccines in Panama: an analysis of two clinical trials.
Lancet Microbe
December 2022
Center for Vaccine Innovation and Access, PATH, Seattle, WA, USA. Electronic address:
Article Synopsis
- Sabin strains in oral poliovirus vaccines (OPV) can revert to harmful forms, prompting the development of a new OPV2 (nOPV2) designed to remain stable and reduce disease-causing strains in populations with low vaccination rates.
- In clinical trials conducted in Panama, infants received either monovalent OPV2 (mOPV2) or nOPV2, and researchers analyzed the poliovirus shed in their stools for genetic and phenotypic changes post-vaccination.
- Results indicated that the Sabin-2 strain rapidly reverts to virulent forms, but nOPV2 showed little to no increase in neurovirulence, indicating it may be a safer option with significantly lower paralysis rates
Quantitative RT-PCR Assays for Quantification of Undesirable Mutants in the Novel Type 2 Oral Poliovirus Vaccine.
Vaccines (Basel)
August 2022
Division of Viral Products, Center for Biologics Evaluation and Research, US Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD 20993, USA.
Emergence of mutations is an inherent property of RNA viruses with several implications for their replication, pathogenesis, and evolutionary adaptation. Oral poliovirus vaccine (OPV), developed by Albert Sabin, is composed of live attenuated polioviruses of three serotypes that can revert to neurovirulence during replication in cell culture and in vaccine recipients. Recently, a new modified variant of Sabin 2 virus was developed by introducing changes in its genome, making it more genetically stable to prevent the reversion.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!